Recently, encorafenib in combination with binimetinib, a MEK inhibitor [22], was approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, based on findings from the COLUMBUS trial [52]. The gene discussed is MAP2K7; the disease is metastatic melanoma.